Edgewise Therapeutics, Inc.
EWTX
$14.60
$0.302.10%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 21.88% | 30.36% | 48.43% | 44.90% | 28.49% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.82% | 32.24% | 34.49% | 37.28% | 50.39% |
| Operating Income | -11.82% | -32.24% | -34.49% | -37.28% | -50.39% |
| Income Before Tax | -14.66% | -43.03% | -31.58% | -32.73% | -46.71% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -14.66% | -43.03% | -31.58% | -32.73% | -46.71% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -14.66% | -43.03% | -31.58% | -32.73% | -46.71% |
| EBIT | -11.82% | -32.24% | -34.49% | -37.28% | -50.39% |
| EBITDA | -11.85% | -32.57% | -34.70% | -37.55% | -51.02% |
| EPS Basic | -2.17% | -31.69% | 10.03% | 10.22% | 0.56% |
| Normalized Basic EPS | -2.19% | -31.63% | 10.01% | 10.19% | 0.57% |
| EPS Diluted | -2.17% | -31.69% | 10.03% | 10.22% | 0.56% |
| Normalized Diluted EPS | -2.19% | -31.63% | 10.01% | 10.19% | 0.57% |
| Average Basic Shares Outstanding | 12.22% | 8.64% | 46.23% | 47.83% | 47.55% |
| Average Diluted Shares Outstanding | 12.22% | 8.64% | 46.23% | 47.83% | 47.55% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |